Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

  1. Mateos, M.-V.
  2. Granell, M.
  3. Oriol, A.
  4. Martinez-Lopez, J.
  5. Blade, J.
  6. Hernandez, M.T.
  7. Martín, J.
  8. Gironella, M.
  9. Lynch, M.
  10. Bleickardt, E.
  11. Paliwal, P.
  12. Singhal, A.
  13. San-Miguel, J.
Aldizkaria:
British Journal of Haematology

ISSN: 1365-2141 0007-1048

Argitalpen urtea: 2016

Alea: 175

Zenbakia: 3

Orrialdeak: 448-456

Mota: Artikulua

DOI: 10.1111/BJH.14263 GOOGLE SCHOLAR